邓薇,沈琳

• 1:首都医科大学附属北京友谊医院普外科
• 2:北京大学临床肿瘤学院北京肿瘤医院消化肿瘤内科

摘要(Abstract)：

胃癌是消化系统常见的恶性肿瘤之一,由于早诊率低,大多数患者在诊断时已经处于疾病中晚期。化疗是进展期胃癌的重要治疗方法,但是,细胞毒性药物联合方案并没有从根本上提高化疗有效率。分子靶向治疗是近年来在治疗血液系统肿瘤和实体瘤中涌现出的新治疗手段。随着对胃癌发生、发展和转移过程中分子生物学机制的研究,这种治疗手段也逐步应用于胃癌治疗的临床实践。这些靶向治疗策略主要包括:HER2单克隆抗体,表皮生长因子受体抑制剂,血管生成抑制剂,多靶点酪氨酸激酶抑制剂,细胞周期蛋白依赖性激酶(CDKs),mTOR抑制剂,c-Met抑制剂,基质金属蛋白酶抑制剂,IGF-1R抑制剂,HSP90抑制剂等。本文就进展期胃癌近年来分子靶向治疗的研究结果及相关进展作一综述。

关键词(KeyWords)： 胃癌;曲妥珠单抗;贝伐单抗;西妥昔单抗;多靶点酪氨酸激酶抑制剂;Favopiridol;RAD001;Figitumumab;17-AAG;Foretinib

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 邓薇,沈琳

参考文献(References)：

• [1]Jemal A,Siegel R,Ward E,et al.Cancer statistics,2008[J].CA Cancer J Clin,2008,58(2):71-96.
• [2]Arteaga C.Targeting HER1/EGFR:a molecular approach to cancer therapy[J].Semin Oncol,2003,30(Suppl7):3-14.
• [3]Lordick F,Leon-Chong J,Kang Y,et al.Her2status ofadvanced gastric cancer is similar in Europe and Asia[J].Ann Oncol,2007,18(Suppl7):253.
• [4]Park DI,Yun JW,Park JH,et al.HER-2/neu amplification is an independent prognostic factor in gastric cancer[J].Dig Dis Sci,2006,51(8):1371-1379.
• [5]Fujimoto-Ouchi K,Sekiguchi F,Yasuno H,et al.Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models[J].Cancer Chemother Pharmacol,2007,59(6):795-805.
• [6]Cortés-Funes H,Rivera F,Alés I,et al.PhaseⅡof trastuzumab and cisplatin in patients(pts)with advanced gastric cancer(AGC)with HER2/neu overexpression/amplification[J].J Clin Oncol,2007,25(18S):4613.
• [7]Y Bang,H Chung.Pathological features of advanced gastric cancer(GC):relationship to human epidermal growth factor receptor2(HER2)positivity in the global screening programme of theToGAtrial[R].ASCO2009,AbstractNo.4556.
• [8]E Van Cutsem,YKang.Efficacy results from theToGAtrial:Aphase III study of trastuzumab added to standard chemotherapy(CT)in first-line human epidermal growth factor receptor2(HER2)-positive advancedgastriccancer(GC)[R].ASCO2009,AbstractNo.LBA4509.
• [9]Arteaga CL.Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia[J].Semin Oncol,2002,29(5Suppl14):3-9.
• [10]Gamboa DA,Dominguez FC,Quintanilla ML,et al.Epidermal growth factor receptor expression correlates with poor survival in gastric adenocarcinoma from Mexican patients:a multivariate analysis using a standardized histochemical detection system[J].Mod Pathol,2004,17(5):579-584.
• [11]Tokunaga A,Onda M,Okuda T,et al.Clinical significance of epidermal growth factor(EGF),EGF receptor,and c-erbB-2in human gastric cancer[J].Cancer,1995,75(6Suppl):1418-1425.
• [12]Drescher D,Moehler M,Gockel I,et al.Coexpression of receptor-tyrosine-kinases in gastric adenocarcinoma:a rationale for a molecular targetingstrategy?[J].WorldJGastroenterol,2007,13(26):3605-3609.
• [13]Kim MA,Lee HS,Lee HE.EGFR in gastric carcinomas:prognostic significance of protein overexpression and high gene copy number[J].Histopathology,2008,52(6):738-746.
• [14]Ciardiello F,Tortora G.A novel approach in the treatment of cancer:targeting the epidermal growth factor receptor[J].Clin Cancer Res,2001,7(10):2958-2970.
• [15]Venook AP.Epidermal growth factor receptor targeted treatment for advanced colorectal carcinoma[J].Cancer,2005,103(2):2435-2446.
• [16]Pinto C,Di Fabio F,Siena S,et al.Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma(FOLCETUX study)[J].Ann Oncol,2007,18(3):510-517.
• [17]Han SW,Oh DY,Im SA,et al.Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6in advanced gastric cancer[J].Br J Cancer,2009,100(2):298-304.
• [18]Zhao W,Chan TL,Chu KM,et al.Mutations of BRAF and KRAS in gastric cancer and their association with microsatellite instability[J].IntJ Cancer,2004,108(1):167-169.
• [19]HY Ma,E Newman.Neoadjuvant therapy of gastric cancerwith cetuximab added to both irinotecan and cisplatin,followed by surgical resection and adjuvant chemoradiation[R].ASCO2009,Abstract#e15552.
• [20]刘慧龙,张小田,徐建明,等.西妥昔单抗联合卡培他滨和顺铂一线治疗晚期胃癌及相关预测因子的研究[J].临床肿瘤学杂志,2009,14(5):385-389.
• [21]G Stella,F Rojas Llimpe.KRAS and BRAF mutational status as response biomarkers to cetuximab combination therapy in advanced gastriccancerpatients[R].ASCO2009,Abstract#15503.
• [22]Veronese ML,O'Dwyer PJ.O'Dwyer.Monoclonal antibodies in the treatment of colorectal cancer[J].Eur J Cancer,2004,40(9):1292-1301.
• [23]Trarbach T,Schleucher N,Weber D,et al.Phase I study of the humanized anti-epidermal growth factor receptor(EGFR)antibody EMD72000(matuzumab)in combination with cisplatin,5-fluorouracil and leucovorin(PFL)in patients(pts)with advanced esophagogastric(EG)adenocarcinoma[J].Proc Am Soc Clin Oncol,2005,24:3156.
• [24]Giusti RM,Shastri KA,Cohen MH,et al.FDA drug approval summary:panitumumab(Vectibix)[J].Oncologist,2007,12(5):577-583.
• [25]Doi T,Koizumi W,Siena S,et al.Efficacy,tolerability and pharmacokinetics of gefitinib(ZD1839)in pretreated patients with metastatic gastric cancer[J].Proc Am Soc Clin Oncol,2003,22:258(A1036).
• [26]Rojo F,Tabernero J,Albanell J,et al.Pharmacodynamic studies of gefitinibintumorbiopsyspecimensfrompatientswithadvancedgastric carcinoma[J].JClinOncol,2006,24(26):4309-4316.
• [27]Dragovich T,McCoy S,Fenoglio-Preiser CM,et al.PhaseⅡtrial of erlotinib in gastroesophageal junction and gastric adenocarcinomas:SWOG0127[J].J Clin Oncol,2006,24(30):4922-4927.
• [28]Ellis LM,Hicklin DJ.VEGF-targeted therapy:mechanisms of anti-tumour activity[J].Nat Rev Cancer,2008,8(8):579-591.
• [29]Maeda K,Chung YS,Ogawa Y,et al.Prognostic value of vascular endothelial growth factor expression in gastric carcinoma[J].Cancer,1996,77(5):858-863.
• [30]Fernando NH,Hurwitz HI.Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer[J].Semin Oncol,2003,30(Suppl6):39-50.
• [31]Shah MA,Ramanathan RK,Ilson DH,et al.Multicenter phase II study of irinotecan,cisplatin,and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinorna[J].J Clin Oncol,2006,24(33):5201-5206.
• [32]JhawerM.PhaseⅡstudyofmodifieddocetaxel,cisplatin,fluorouracil(mDCF),and bevacizumab(BEV)in patients with metastatic gastroesophageal(GE)adenocarcinoma[R].American Society of ClinicalOncologyGICancerSymposium2009,abstract#10.
• [33]Nalluri SR,Chu D,Keresztes R,et al.Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancerpatients:ameta-analysis[J].JAMA,2008,300(19):2277-2285.
• [34]Scappaticci FA,Skillings JR,Holden SN,et al.Arterial thromboembolic events and patients with metastatic carcinoma treated with chemotherapy and bevacizumab[J].J Natl Cancer Inst,2007,99(16):1232-1239.
• [35]Y Kang,A Ohtsu,E Van Cutsem,et al.AVAGAST:A randomized,double-blind,placebo-controlled,phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer(AGC)[J].J Clin Oncol,2010,28:18s(suppl;abstr LBA4007).
• [36]Tokuyama J,Kubota T,Saikawa Y,et al.Tyrosine kinase inhibitor SU6668inhibits peritoneal dissemination of gastric cancer via supresionof tumor angiogenesis[J].Anticancer Res,2005,25(1A):17-22.
• [37]McCarty MF,Wey J,Stoeltzing O,et al.ZD6474,a vascular endothelial growth factor receptor tyrosine kinase,inhibits orthotopic growth and angiogenesis of gastric cancer[J].Mol Cancer Ther,2004,3(9):1041-1048.
• [38]Cameron D,Casey M,Press M,et al.A phaseⅢrandomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab:updated efficacy and biomarker analyses[J].Breast Cancer Res Treat,2008,112(3):533-543.
• [39]Iqbal S,Goldman B.S0413:a phaseⅡSWOG study of GW572016(lapatinib)as first line therapy in patients(pts)with advanced or metastatic gastric cancer[J].J Clin Oncol,2007,25(abstract4621).
• [40]Chang H,Azuma M,Goldman B,et al.Gene expression levels of HER2and IL-8and polymorphism in IL-8associated with clinical outcome in advanced or metastatic gastric cancer treated with lapatinib in SWOG0413trial[J].J Clin Oncol,2007,25(abstract4647).
• [41]Bang Y,Kang Y,Kang W,et al.Sunitinib as second-line treatment for advanced gastric cancer:preliminary results from a phaseⅡstudy[R].ASCO2007,abstract#4603.
• [42]Moehler M.,Hartmann J,Lordick F,et al.Sunitinib in patients with chemo-refractory metastatic gastric cancer:preliminary results of an open-label,prospective nonrandomised multicentre AIO phaseⅡtrial[R].American Society of Clinical Oncology GI Cancer Symposium,2009,15-17.
• [43]Sun W,Powell ME,O'Dwyer RH,et al.A phaseⅡstudy:combination of sorafenib with docetaxel and cisplatin in the treatment of metastatic or advanced unresectable gastric and gastroesophageal junction(GEJ)adenocarcinoma(ECOG5303)[R].ASCO2008,abstract#4535.
• [44]Senderowicz AM.Small molecule modulators of cyclin-dependent kinases for cancer therapy.Oncogene2000;19(56):6600-6606.
• [45]夏研,徐红,孙岩,等.幽门螺旋杆菌感染与胃癌中CDK1表达的关系[J].中国实用内科杂志,2010,22(3):266-267.
• [46]Wang HK.Flavopiridol.National Cancer Institute[J].Curr Opin Investig Drugs,2001,2(8):1149-1155.
• [47]Schwartz GK,Ilson D,Saltz L,et al.PhaseⅡstudy of the cyclin-dependent kinase inhibitor favopiridol administered to patients with advanced gastric carcinoma[J].J Clin Oncol,2001,19(7):1985-1992.
• [48]Motwani M,Rizzo C,Sirotnak F,et al.Flavopiridol enhances the effect of docetaxel in vitro and in vivo in human gastric cancer cells[J].Mol Cancer Ther,2003,2(6):549-555.
• [49]Kozma SC,Thomas G.Regulation of cell size in growth,development and human disease:PI3K,PKB and S6K[J].Bioassays,2002,24(1):65-71.
• [50]Vignot S,Faivre S,Aguirre D,et al.mTOR targeted therapy of cancer withrapamycinderivatives[J].AnnOncol,2005,16(4):525-537.
• [51]Yu G,Wang J,Chen Y,et al.Overexpression of phosphorylated mammaliantarget of rapamycin predicts lymph node metastasis and prognosis of Chinese patients with gastric cancer[J].Clin Cancer Res,2009,15(5):1821-1829.
• [52]Faivre S,Kroemer G,Raymond E.Current development of mTOR inhibitors as anticancer agents[J].Nat Rev Drug Discov,2006,5(8):671-688.
• [53]Guba M,Koehl GE,Neppl E,et al.Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer[J].Transpl Int,2005,18(1):89-94.
• [54]CejkaD,PreusserM,WoehrerA,etal.Everolimus(RAD001)andanti-angiogeniccyclophosphamideshowlong-termcontrolofgastriccancer growthinvivo[J].CancerBiolTher,2008,7(9):1377-1385.
• [55]Muro K,Boku N,Yamada Y,et al.Multicenter phaseⅡstudy of RAD001for previously treated metastatic gastric cancer(MGC):preliminary results[J].J Clin Oncol,2009,26:4541.
• [56]Maulik G,Shrikhande A,Kijima T,et al.Role of the hepatocyte growth factor receptor,c-Met,in oncogenesis and potential for therapeutic inhibition[J].Cytokine Growth Factor Rev,2002,13(1):41-59.
• [57]Wang SY,Chen B,Zhan YQ,et al.SU5416is a potent inhibitor of hepatocyte growth factor receptor(c-Met)and blocks HGF-induced invasiveness of human HepG2hepatoma cells[J].J Hepatol2004,41(2):267-273.
• [58]Corso S,Comoglio PM,Giordano S.Cancer therapy:can the challenge be MET?[J].Trends Mol Med,2005,11(6):284-292.
• [59]Ferracini R,Olivero M,Di Renzo MF,et al.Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas[J].Oncogene,1996,12(8):1697-1705.
• [60]Nakajima M,Sawada H,YamadaY,et al.The prognostic significance of amplification and overexpression of c-met and c-erb B-2in human gastriccarcinomas[J].Cancer,1999,85(9):1894-1902.
• [61]DrebberU,BaldusSE,NoldenB,etal.Theoverexpressionofc-metas a prognostic indicator for gastric carcinoma compared to p53and p21nuclearaccumulation[J].OncolRep,2008,19(6):1477-1483.
• [62]Jhawer M,Kindler H,Wainberg Z,et al.Assessment of two dosing schedulesofGSK1363089(GSK089),adualMET/VEGFR2inhibitor,inmetastaticgastriccancer(GC):InterimresultsofamulticenterphaseⅡstudy[J].JClinOncol,2009,27:4502.
• [63]Kwak F.Clinical activity observed in a phase I dose escalation trialof anoral c-met and ALK inhibitor,PF-02341066[R].ASCO2009,abstract83509.
• [64]Monig SP,Baldus SE,Hennecken JK,et al.Expression of MMP-2is associated with progression and lymph node metastasis of gastric carcinoma[J].Histopathology,2001,39(6):597-602
• [65]Kimata M,Otani Y,Kubota T,et al.Matrix metalloproteinase inhibitors,marimastat,decreasesperitonealspreadofgastriccarcinoma innudemice[J].JpnJCancerRes,2003,93(7):834-841.
• [66]Bramhall SR,Hallissey MT,Whiting J,et al.Marimastat as maintenance therapy for patients with advanced gastric cancer:a randomised trial[J].Br J Cancer,2002,86(12):1864-1870.
• [67]Grimber A,Cohen P.Role of insulin-like growth factor and their binding proteins in growth control and carcinogenesis[J].J Cell Physiol,2000,183(1):1-9.
• [68]Dupont J,Karas M,LeRoith D.The cyclin-dependent kinase inhibitor p21CIP/WAF is a positive regulator of insulin-like growth factor I-induced cell proliferation in MCF-7human breast cancer cells[J].J Biol Chem,2003,278(39):37256-37264.
• [69]Matsubara J,Yamada Y,Hirashima Y,et al.Impact of insulin-like growth factor type1receptor,epidermal growth factor receptor,and HER2expressions on outcomes of patients with gastric cancer[J].Clin Cancer Res,2008,14(10):3022-3029.
• [70]Jiang Y,Wang L,GongW,et al.A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1and regional lymph node metastasis of human gastric cancer[J].Clin Exp Metastasis,2004,21(8):755-764.
• [71]Attard G,Fong PC,Molife R,et al.PhaseⅠtrial involving the pharmacodynamic(PD)study of circulating tumour cells,of CP-751,871,a monoclonal antibody against the insulin-like growth factor1receptor(IGF-1R),with docetaxel(D)in patients with advanced cancer[J].J Clin Oncol,2006,22(9):10-14.
• [72]Pearl LH,Prodromou C.Structure,function,and mechanism of the Hsp90molecular chaperone[J].Adv Protein Chem,2001,59:157-186.
• [73]Tsutsumi S,Neckers L.Extracellular heat shock protein90:a role for a molecular chaperone in cell motility and cancer metastasis[J].Cancer Sci,2007,98(10):1536-1539.
• [74]Isaacs JS,Xu W,Neckers L.Heat shock protein90as amolecular target for cancer therapeutics[J].Cancer Cell,200,3(3):213-217.
• [75]Zuo DS,Dai J,Bo AH,et al.Significance of expression of heat shock protein90αin human gastric cancer[J].World J Gastroenterol,2003,9(11):2616-2618.
• [76]Marcu MG,Schulte TW,Neckers L.Novobiocin and related coumerins and depletion of heat shock protein90-dependent signaling proteins[J].J Natl Cancer Inst,2000,92(3):242-248.
• [77]Paduano F,villa R,Pennati M,et al.Silencing of surviving gene by small interfering RNAs produces supraaddifive growth suppression in combination with17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells[J].Mal Cancer Ther,2006,5(1):179-186.
• [78]Chiosis G,Huezo H,Rosen N,et a1.17AAG:low target binding affinity and potent cell activity-finding an explanation[J].MolCane Therap,2003,2(2):123-129.
• [79]高志军,赵春临,乔军波,等.HSP90抑制剂17-DMAG对胃癌细胞株SGC-7901增殖及凋亡的影响[J].世界华人消化杂志,2008,16(29):3269-3273.